Clinical trial
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional…
NCT00191555 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191555 |
|---|---|
| Title | Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment |
| Official title | Double-Blind Long-term Study Comparing the Efficacy and Safety of Olanzapine Versus Haloperidol in Patients With Schizophrenia Previously Stabilized With Conventional Antipsychotic Treatment |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | olanzapine, haloperidol |
| Enrollment | 360 |
| Start date | Aug 1, 2003 |
| Completion | May 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 12, 2012 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: